What do systematic reviews say?

Ursodeoxycholic acid vs placebo or no intervention

It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality compared with placebo or no intervention (very low certainty).

• Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
  RR 0.97 [0.67, 1.42]
  14 studies · 1391 participants
  Very low

Ursodeoxycholic acid vs placebo or no intervention

It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality or liver transplantation compared with placebo or no intervention (very low certainty).

• Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
  RR 0.96 [0.74, 1.25]
  15 studies · 1419 participants
  Very low

Ursodeoxycholic acid vs placebo

It is very uncertain whether ursodeoxycholic acid changes mortality compared with placebo (very low certainty).

• Pharmacological interventions for primary sclerosing cholangitis 2017 · Cochrane Headline outcomes only
  OR 1.51 [0.63, 3.63]
  2 studies · 348 participants
  Very low

Ursodeoxycholic acid vs no intervention

It is very uncertain whether ursodeoxycholic acid (UDCA) changes mortality at maximal compared with no intervention (very low certainty).

• Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
  OR 0.99 [0.6, 1.64]
  6 studies · 734 participants
  Very low

Colchicine plus ursodeoxycholic acid (UDCA) vs UDCA

It is very uncertain whether colchicine plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).

• Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
  OR 1.84 [0.38, 8.91]
  2 studies · 158 participants
  Very low

Methotrexate plus ursodeoxycholic acid (UDCA) vs UDCA

It is very uncertain whether methotrexate plus ursodeoxycholic acid (UDCA) changes mortality at maximal compared with UDCA (very low certainty).

• Pharmacological interventions for primary biliary cholangitis 2017 · Cochrane Headline outcomes only
  OR 1.17 [0.55, 2.51]
  2 studies · 290 participants
  Very low

Ursodeoxycholic acid vs placebo or no treatment

Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  RR 0.7 [0.5, 0.99]
  4 studies · 612 participants
  Low

Ursodeoxycholic acid vs placebo or no treatment

It is very uncertain whether summary of findings: Ursodeoxycholic acid changes mortality attributable to hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  RR 0.27 [0.09, 0.87]
  4 studies · 612 participants
  Very low

Intervention not reported

• Ursodeoxycholic acid for cystic fibrosis‐related liver disease 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 58 participants
  Low

Bezafibrate vs ursodeoxycholic acid

It is very uncertain whether bezafibrate changes all‐cause mortality compared with ursodeoxycholic acid (very low certainty).

• Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
  RD 0
  2 studies · 69 participants
  Very low